It will be very interesting to see if LL Product Insert recommends CCR5 occupancy testing. As medicine becomes more personalized, we are seeing many Cancer drug PI's ( among other drugs) recommend certain testing prior to initiating therapy. In my opinion this could be a reason for the distancing of BP and CytoDyn. It would be a conflict in my opinion to be the owner of both therapy and diagnostic.

I do think that the launch of the test kits is a good indicator though. It would be pointless to test a person for CCR5 receptor occupancy if there was not a therapy available that required this information. It begs the question when the results come back.....ok great we know that there is 100% occupancy.....do we then send the patient on their merry way?? or say "noted" No! The next step is LL. Or another therapy that does the same thing, but there isn't one so for now it's LL. In my opinion this a fantastic "pull through" strategy- if I am a long hauler and ask my doc to run this test, or a doc who requests this test my next step is to start demanding LL.

I can't imagine launching a DX- sales force and all with no market but clinical trial sites.

Sorry for the rant!


Either way the pressure is ON!